Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zymes, a New Jersey-based biopharmaceutical company, has received a two-year $476,000 grant from the Michael J Fox Foundation (MJFF), under the Therapeutics Development Initiative Fall 2010 Program, to evaluate the effectiveness of WS-CoQ10 in stopping the progressive loss of dopamine nerve cells in animal models of Parkinson's disease (PD).
Subscribe to our email newsletter
Zymes is engaged in developing a novel, water-soluble, readily applicable patented formulation of nano-micellar complex of CoQ10 and pro-drug form of vitamin E (WS-CoQ10), licensed from the National Research Council Canada.
CoQ10’s efficacy in the brain may increase through Zymes’ formulation and allow its use at lower dosages.
The formulation offers a near-complete protection for dopamine nerve cells in the pre-clinical models of PD as a result of its prophylactic application.
Zymes CEO Vincent Morano said the recognition of the significant potential of Zymes’ technology by the Michael Fox Foundation will strengthen the alliance between the organizations.
The project, ‘Evaluation of the Neuroprotectivity Ability of Zymes’ Water-soluble CoQ10 (WS-CoQ10) in Animal Models of PD (Parkinson’s disease): Preclinical Validation and Dose Optimizations for Clinical Study,’ will be conducted by Zymes in collaboration with the National Research Council of Canada (NRC) and the University of Windsor (Ontario, Canada.